McNeil Hannah C, Jefferies Johanna M C, Clarke Stuart C
University of Southampton Malaysia Campus, No.3, Persiaran Canselor 1, Kota Ilmu, Educity, Iskandar, 79200 Nusajaya, Johor, Malaysia.
Faculty of Medicine and Institute of Life Sciences, University of Southampton, Southampton, UK
Expert Rev Anti Infect Ther. 2015 Jun;13(6):705-14. doi: 10.1586/14787210.2015.1033401.
Worldwide bacterial meningitis accounts for more than one million cases and 135,000 deaths annually. Profound, lasting neurological complications occur in 9-25% of cases. This review confirms the greatest risk from bacterial meningitis is in early life in Malaysia. Much of the disease burden can be avoided by immunization, particularly against Haemophilus influenzae type b (Hib) and Streptococcus pneumoniae. Despite inclusion of the Hib vaccine in the National Immunisation Programme and the licensure of pneumococcal vaccines, these two species are the main contributors to bacterial meningitis in Malaysia, with Neisseria meningitidis and Mycobacterium tuberculosis, causing a smaller proportion of disease. The high Hib prevalence may partly be due to dated, small-scale studies limiting the understanding of the current epidemiological situation. This highlights the need for larger, better quality surveillance from Malaysia to evaluate the success of Hib immunization and to help guide immunization policy for vaccines against S. pneumoniae and N. meningitidis.
全球范围内,细菌性脑膜炎每年导致超过100万例病例和13.5万例死亡。9%至25%的病例会出现严重、持久的神经并发症。本综述证实,在马来西亚,细菌性脑膜炎的最大风险出现在生命早期。通过免疫接种,尤其是针对b型流感嗜血杆菌(Hib)和肺炎链球菌的免疫接种,可以避免很大一部分疾病负担。尽管Hib疫苗已纳入国家免疫规划且肺炎球菌疫苗已获许可,但这两种细菌仍是马来西亚细菌性脑膜炎的主要病因,脑膜炎奈瑟菌和结核分枝杆菌导致的疾病占比相对较小。Hib的高流行率可能部分归因于过时的小规模研究,这些研究限制了对当前流行病学状况的了解。这凸显了马来西亚需要开展规模更大、质量更高的监测,以评估Hib免疫接种的成效,并帮助指导针对肺炎链球菌和脑膜炎奈瑟菌疫苗的免疫政策。